10x Genomics, Inc. (TXG) stock
TXGNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 9/30113% above fair value
$57.07+0.77 (+1.37%)
Close on Nov 18, 2026Market cap $7.44BP/E –Yield –
10x Genomics shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
10x Genomics's shares outstanding was 131M at Sep 30, 2026. For fiscal 2025 it was 125M, up 3.6% from the year before. The highest annual figure on record is 125M in fiscal 2025.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 125M | +3.6% |
| FY2024 | Dec 31, 2024 | 120M | +2.8% |
| FY2023 | Dec 31, 2023 | 117M | +2.9% |
| FY2022 | Dec 31, 2022 | 114M | +3.2% |
| FY2021 | Dec 31, 2021 | 110M | +9.1% |
| FY2020 | Dec 31, 2020 | 101M | +158.8% |
| FY2019 | Dec 31, 2019 | 39M | +191.9% |
| FY2018 | Dec 31, 2018 | 13M | +15.6% |
| FY2017 | Dec 31, 2017 | 12M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 131M | +4.2% |
| Q2 FY2026 | Jun 30, 2026 | 130M | +4.4% |
| Q1 FY2026 | Mar 31, 2026 | 128M | +4.6% |
| Q4 FY2025 | Dec 31, 2025 | 127M | +4.5% |
| Q3 FY2025 | Sep 30, 2025 | 126M | +4.0% |
| Q2 FY2025 | Jun 30, 2025 | 125M | +3.7% |
| Q1 FY2025 | Mar 31, 2025 | 123M | +2.7% |
| Q4 FY2024 | Dec 31, 2024 | 122M | +2.5% |
| Q3 FY2024 | Sep 30, 2024 | 121M | +2.6% |
| Q2 FY2024 | Jun 30, 2024 | 120M | +2.9% |
| Q1 FY2024 | Mar 31, 2024 | 119M | +3.3% |
| Q4 FY2023 | Dec 31, 2023 | 119M | +3.3% |
| Q3 FY2023 | Sep 30, 2023 | 118M | +3.2% |
| Q2 FY2023 | Jun 30, 2023 | 117M | +2.8% |
| Q1 FY2023 | Mar 31, 2023 | 116M | +2.3% |
| Q4 FY2022 | Dec 31, 2022 | 115M | +2.6% |
| Q3 FY2022 | Sep 30, 2022 | 114M | +2.9% |
| Q2 FY2022 | Jun 30, 2022 | 114M | +3.4% |
| Q1 FY2022 | Mar 31, 2022 | 113M | +3.9% |
| Q4 FY2021 | Dec 31, 2021 | 112M | +4.2% |
| Q3 FY2021 | Sep 30, 2021 | 111M | +9.4% |
| Q2 FY2021 | Jun 30, 2021 | 110M | +11.0% |
| Q1 FY2021 | Mar 31, 2021 | 109M | +12.3% |
| Q4 FY2020 | Dec 31, 2020 | 107M | +268.1% |
| Q3 FY2020 | Sep 30, 2020 | 101M | +550.9% |
| Q2 FY2020 | Jun 30, 2020 | 99M | +568.7% |
| Q1 FY2020 | Mar 31, 2020 | 97M | +591.4% |
| Q3 FY2019 | Sep 30, 2019 | 29M | +114.8% |
| Q2 FY2019 | Jun 30, 2019 | 16M | – |
| Q1 FY2019 | Mar 31, 2019 | 15M | – |
| Q4 FY2018 | Dec 31, 2018 | 14M | – |
| Q3 FY2018 | Sep 30, 2018 | 14M | – |
See a number that looks wrong?